-
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:215-8. -
Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
Bombard AT, Akolekar R, Farkas DH, Vanagtmael AL, Aquino F, Oeth P, Nicolaides KH.
Prenat Diagn 2011;31:802-8. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Maternal serum progesterone-induced blocking factor at 11-13 weeks gestation in spontaneous early preterm delivery.
Beta J, Szekeres-Bartho J, Skyfta E, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;29:197-200. -
Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18.
Ashoor G, Maiz N, Cuckle H, Jawdat F, Nicolaides KH.
Prenat Diagn 2011;31:33-7. -
Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery.
Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
Obstet Gynecol 2011;117:293-8. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH.
Prenat Diagn 2011;31:38-45. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Fetal RHD Genotyping in Maternal Plasma at 11-13 Weeks of Gestation.
Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.
Fetal Diagn Ther 2011;29:301-6. -
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J.
FASEB J 2002;16:1271-3. -
Cervical screening for preterm delivery.
Welsh A, Nicolaides K.
Curr Opin Obstet Gynecol 2002;14:195-202. -
Elective cerclage vs ultrasound-indicated cerclage in high-risk pregnancies.
To MS, Palaniappan V, Skentou C, Gibb D, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;19:475-7. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
Congenital nephrotic syndrome presenting with increased nuchal translucency in the first trimester.
Souka AP, Skentou H, Geerts L, Bower S, Nicolaides KH.
Prenat Diagn 2002;22:93-5. -
Congenital lymphedema presenting with increased nuchal translucency at 13 weeks of gestation.
Souka AP, Krampl E, Geerts L, Nicolaides KH.
Prenat Diagn 2002;22:91-2. -
Hypophosphatasia associated with increased nuchal translucency: a report of two affected pregnancies.
Souka AP, Raymond FL, Mornet E, Geerts L, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:294-5. -
Blackfan-Diamond anemia and dyserythropoietic anemia presenting with increased nuchal translucency at 12 weeks of gestation.
Souka AP, Bower S, Geerts L, Huggon I, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:197-9.